In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...
The Healthy on MSN13d
More Eye Drops Have Been Recalled NationwideThe product may be used to treat a condition that the American Academy of Ophthalmology says affects around 20 million ...
Oculis' main value driver appears to be OCS-01, which targets a respectable $4B DME TAM with its non-invasive eye drops. See ...
About XDEMVY ® XDEMVY (lotilaner ophthalmic solution, 0.25%), formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root ...
The global ophthalmic sprays market, valued at USD 343 million in 2023, is projected to experience exponential growth, ...
What’s Causing National Vision Holdings Inc (EYE) Stock’s -20.88% Drop Over the Last Six Months?
National Vision Holdings Inc (EYE) stock saw a modest uptick, ending the day at $10.8 which represents a slight increase of $0.05 or 0.47% from the prior close of $10.75. The stock opened at $11 and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback